Cargando…

Structural signature of the G719S-T790M double mutation in the EGFR kinase domain and its response to inhibitors

Some individuals with non-small-cell lung cancer (NSCLC) benefit from therapies targeting epidermal growth factor receptor (EGFR), and the characterization of a new mechanism of resistance to the EGFR-specific antibody gefitinib will provide valuable insight into how therapeutic strategies might be...

Descripción completa

Detalles Bibliográficos
Autores principales:	C., George Priya Doss, B., Rajith, Chakraborty, Chiranjib, N., NagaSundaram, Ali, Shabana Kouser, Zhu, Hailong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4121614/ https://www.ncbi.nlm.nih.gov/pubmed/25091415 http://dx.doi.org/10.1038/srep05868

Ejemplares similares

Evolution- and Structure-Based Computational Strategy Reveals the Impact of Deleterious Missense Mutations on MODY 2 (Maturity-Onset Diabetes of the Young, Type 2)
por: George, Doss C. Priya, et al.
Publicado: (2014)

Extrapolating the effect of deleterious nsSNPs in the binding adaptability of flavopiridol with CDK7 protein: a molecular dynamics approach
por: George Priya Doss, C, et al.
Publicado: (2013)

Investigating the Structural Impacts of I64T and P311S Mutations in APE1-DNA Complex: A Molecular Dynamics Approach
por: Doss, C. George Priya, et al.
Publicado: (2012)

Exploration of structural stability in deleterious nsSNPs of the XPA gene: A molecular dynamics approach
por: NagaSundaram, N, et al.
Publicado: (2011)

Analysing the Effect of Mutation on Protein Function and Discovering Potential Inhibitors of CDK4: Molecular Modelling and Dynamics Studies
por: N, Nagasundaram, et al.
Publicado: (2015)

Virtual screening of the inhibitors targeting at the viral protein 40 of Ebola virus
por: Karthick, V., et al.
Publicado: (2016)

CoagVDb: a comprehensive database for coagulation factors and their associated SAPs
por: Ali, Shabana Kouser, et al.
Publicado: (2015)

Osimertinib Treatment Was Unsuccessful for Lung Adenocarcinoma with G719S, S768I, and T790M Mutations
por: Nasu, Shingo, et al.
Publicado: (2018)

Mechanism of artemisinin resistance for malaria PfATP6 L263 mutations and discovering potential antimalarials: An integrated computational approach
por: N., Nagasundaram, et al.
Publicado: (2016)

Integrating In Silico Prediction Methods, Molecular Docking, and Molecular Dynamics Simulation to Predict the Impact of ALK Missense Mutations in Structural Perspective
por: Priya Doss, C. George, et al.
Publicado: (2014)

Rising Strengths Hong Kong SAR in Bioinformatics
por: Chakraborty, Chiranjib, et al.
Publicado: (2016)

Zika: How safe is India?
por: Doss, C. George Priya, et al.
Publicado: (2017)

Overcoming EGFR T790M-based Tyrosine Kinase Inhibitor Resistance with an Allele-specific DNAzyme
por: Lai, Wei-Yun, et al.
Publicado: (2014)

EGFR T790M: revealing the secrets of a gatekeeper
por: Ko, Brian, et al.
Publicado: (2017)

Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer
por: Masuda, Takeshi, et al.
Publicado: (2023)

Exceptional response to afatinib in a patient with persistent G719A EGFR-mutant NSCLC
por: Kulkarni, Amit A, et al.
Publicado: (2022)

Poster Sessions 555 - 719
Publicado: (2003)

Path to Facilitate the Prediction of Functional Amino Acid Substitutions in Red Blood Cell Disorders – A Computational Approach
por: B, Rajith, et al.
Publicado: (2011)

Computational Refinement of Functional Single Nucleotide Polymorphisms Associated with ATM Gene
por: George Priya Doss, C., et al.
Publicado: (2012)

A rare case of double primary lung adenocarcinomas with uncommon complex EGFR G719X and S768I mutations and pleomorphic carcinoma
por: Morimoto, Toshiki, et al.
Publicado: (2023)

Optimizing Sequential Treatment With EGFR Tyrosine Kinase Inhibitor With a Simulation of the T790M Mutation Rate in EGFR–Mutated Lung Cancer
por: Haratake, Naoki, et al.
Publicado: (2020)

First‐line osimertinib treatment in a patient with lung adenocarcinoma with coexisting epidermal growth factor receptor G719S and de novo T790M mutations
por: Ito, Noriaki, et al.
Publicado: (2022)

A Radiobrominated Tyrosine Kinase Inhibitor for EGFR with L858R/T790M Mutations in Lung Carcinoma
por: Fawwaz, Muammar, et al.
Publicado: (2021)

EGFR tyrosine kinase inhibitor HS-10182 increases radiation sensitivity in non-small cell lung cancers with EGFR T790M mutation
por: Chen, Yang, et al.
Publicado: (2018)

EGFR T790M Mutation as a Possible Target for Immunotherapy; Identification of HLA-A*0201-Restricted T Cell Epitopes Derived from the EGFR T790M Mutation
por: Yamada, Teppei, et al.
Publicado: (2013)

719. Clinical Outcomes of Single versus Double Anaerobic Coverage for Intra-abdominal Infections
por: Raymond, Lendelle, et al.
Publicado: (2020)

Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution
por: Li, Kaidi, et al.
Publicado: (2017)

A case report of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with T790M mutation and epithelial-to-mesenchymal transition
por: Zhang, Nana, et al.
Publicado: (2017)

Multiple intraventricular metastases from lung adenocarcinoma with EGFR G719X mutation: a case report
por: Kong, Chen, et al.
Publicado: (2020)

Detection of the EGFR G719S Mutation in Non-small Cell Lung Cancer Using Droplet Digital PCR
por: Esteva-Socias, Margalida, et al.
Publicado: (2020)

Micro-Environmental Signature of The Interactions between Druggable Target Protein, Dipeptidyl Peptidase-IV, and Anti-Diabetic Drugs
por: Chakraborty, Chiranjib, et al.
Publicado: (2017)

Understanding the conservation patterns and molecular phylogenetics of human death receptors family through computational biology
por: Tomar, Jinny, et al.
Publicado: (2013)

EGFR Thr790Leu as a Potential Resistance Mechanism to First-Generation EGFR Tyrosine Kinase Inhibitor May Respond to Osimertinib in Patients With Lung Adenocarcinoma
por: Xiang, Chan, et al.
Publicado: (2021)

Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR‐T790M mutation in non‐small cell lung cancer cells
por: Katayama, Yuki, et al.
Publicado: (2022)

Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, “uncommon-G719X, S768I, L861Q”) Among the Third-Generation EGFR TKIs?
por: Zhang, Shannon S, et al.
Publicado: (2022)

Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFR(WT), EGFR(T790M), and EGFR(L858R))
por: Abo Al-Hamd, Mahmoud G., et al.
Publicado: (2023)

Development of New Mouse Lung Tumor Models Expressing EGFR T790M Mutants Associated with Clinical Resistance to Kinase Inhibitors
por: Regales, Lucia, et al.
Publicado: (2007)

Uncovering the Mechanism of Drug Resistance Caused by the T790M Mutation in EGFR Kinase From Absolute Binding Free Energy Calculations
por: Zhou, Huaxin, et al.
Publicado: (2022)

Structure-activity exploration of a small-molecule allosteric inhibitor of T790M/L858R double mutant EGFR
por: Foschi, Francesca, et al.
Publicado: (2022)

In silico insight into EGFR treatment in patients with lung carcinoma and T790M mutations
por: Zang, Shu-Zhi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hvkgovldrf9af9u02tqc19eiff